Induced tigecycline resistance in Streptococcus pneumoniae mutants reveals mutations in ribosomal proteins and rRNA

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 11, 2015, Pages 2973-2980

  Lupien, Andréanne ^a   Gingras, Hélène ^a   Leprohon, Philippe ^a   Ouellette, Marc ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

RIBOSOMAL PROTEIN S3; RIBOSOMAL PROTEINS S10; RIBOSOME PROTEIN; RNA 16S; TIGECYCLINE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; MINOCYCLINE; RIBOSOME DNA;

ANTIBIOTIC RESISTANCE; ARTICLE; GENE MUTATION; GENOME ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; NEXT GENERATION SEQUENCING; NONHUMAN; STREPTOCOCCUS PNEUMONIAE; ANALOGS AND DERIVATIVES; DNA MUTATIONAL ANALYSIS; DNA SEQUENCE; DRUG EFFECTS; GENETIC SELECTION; GENETICS; MOLECULAR GENETICS; MUTATION;

ANTI-BACTERIAL AGENTS; DNA MUTATIONAL ANALYSIS; DNA, RIBOSOMAL; DRUG RESISTANCE, BACTERIAL; MINOCYCLINE; MOLECULAR SEQUENCE DATA; MUTATION; RIBOSOMAL PROTEINS; SELECTION, GENETIC; SEQUENCE ANALYSIS, DNA; STREPTOCOCCUS PNEUMONIAE;

EID: 84949034614     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv211     Document Type: Article

References (69)

1. Mera R, Miller LA, Fritsche TR et al. Serotype replacement and multiple resistance in Streptococcus pneumoniae after the introduction of the conjugate pneumococcal vaccine. Microb Drug Resist 2008; 14: 101-7.
2. Song JH, Dagan R, Klugman KP et al. The relationship between pneumococcal serotypes and antibiotic resistance. Vaccine 2012; 30: 2728-37.
3. Song JH, Jung SI, Ko KS et al. High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study). Antimicrob Agents Chemother 2004; 48: 2101-7.
4. Hackel M, Lascols C, Bouchillon S et al. Serotype prevalence and antibiotic resistance in Streptococcus pneumoniae clinical isolates among global populations. Vaccine 2013; 31: 4881-7.
5. Izdebski R, Sadowy E, Fiett J et al. Clonal diversity and resistance mechanisms in tetracycline-nonsusceptible Streptococcus pneumoniae isolates in Poland. Antimicrob Agents Chemother 2007; 51: 1155-63.
6. McGee L, McDougal L, Zhou J et al. Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae defined by the pneumococcal molecular epidemiology network. J Clin Microbiol 2001; 39: 2565-71.
7. Johnson JR. Doxycycline for treatment of community-acquired pneumonia. Clin Infect Dis 2002; 35: 632; author reply 632-3.
8. Mokabberi R, Haftbaradaran A, Ravakhah K. Doxycycline vs. levofloxacin in the treatment of community-acquired pneumonia. J Clin Pharm Ther 2010; 35: 195-200.
9. Lederman ER, Gleeson TD, Driscoll T et al. Doxycycline sensitivity of S. pneumoniae isolates. Clin Infect Dis 2003; 36: 1091.
10. Frampton JE, Curran MP. Tigecycline. Drugs 2005; 65: 2623-35; discussion 2636-7.
11. File TM Jr. Streptococcus pneumoniae and community-acquired pneumonia: a cause for concern. Am J Med 2004; 117 Suppl 3A: 39S-50S.
12. Sum PE, Lee VJ, Testa RT et al. Glycylcyclines. 1. A new generation of potent antibacterial agents through modification of 9-aminotetracyclines. J Med Chem 1994; 37: 184-8.
13. Hoellman DB, Pankuch GA, Jacobs MR et al. Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother 2000; 44: 1085-8.
14. Murphy TM, Deitz JM, Petersen PJ et al. Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis. Antimicrob Agents Chemother 2000; 44: 3022-7.
15. Jenner L, Starosta AL, Terry DS et al. Structural basis for potent inhibitory activity of the antibiotic tigecycline during protein synthesis. Proc Natl Acad Sci USA 2013; 110: 3812-6.
16. Bauer G, Berens C, Projan SJ et al. Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drugdirected Fe2+ cleavage of 16S rRNA. J Antimicrob Chemother 2004; 53: 592-9.
17. Bergeron J, Ammirati M, Danley D et al. Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection. Antimicrob Agents Chemother 1996; 40: 2226-8.
18. Rose WE, Rybak MJ. Tigecycline: first of a new class of antimicrobial agents. Pharmacotherapy 2006; 26: 1099-110.
19. Petersen PJ, Jacobus NV,WeissWJ et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999; 43: 738-44.
20. Doan TL, Fung HB, Mehta D et al. Tigecycline: a glycylcycline antimicrobial agent. Clin Ther 2006; 28: 1079-106.
21. Fluit AC, Florijn A, Verhoef J et al. Presence of tetracycline resistance determinants and susceptibility to tigecycline and minocycline. Antimicrob Agents Chemother 2005; 49: 1636-8.
22. Brandon M, Dowzicky MJ. Antimicrobial susceptibility among Gram-positive organisms collected from pediatric patients globally between 2004 and 2011: results from the Tigecycline Evaluation and Surveillance Trial. J Clin Microbiol 2013; 51: 2371-8.
23. Jones RN, Castanheira M, Hu B et al. Update of contemporary antimicrobial resistance rates across China: reference testing results for 12 medical centers (2011). Diagn Microbiol Infect Dis 2013; 77: 258-66.
24. Pillar CM, Draghi DC, Dowzicky MJ et al. In vitro activity of tigecycline against gram-positive and gram-negative pathogens as evaluated by broth microdilution and Etest. J Clin Microbiol 2008; 46: 2862-7.
25. Balode A, Punda-Polic V, Dowzicky MJ. Antimicrobial susceptibility of gram-negative and gram-positive bacteria collected from countries in Eastern Europe: results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) 2004-2010. Int J Antimicrob Agents 2013; 41: 527-35.
26. Kanj SS, Whitelaw A, Dowzicky MJ. In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011. Int J Antimicrob Agents 2014; 43: 170-8.
27. Norskov-Lauritsen N, Marchandin H, Dowzicky MJ. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007). Int J Antimicrob Agents 2009; 34: 121-30.
28. Bouchillon SK, Hoban DJ, Johnson BM et al. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004). Diagn Microbiol Infect Dis 2005; 52: 173-9.
29. Arya SC, Agarwal N. Emergence of tigecycline resistance amongst multi-drug resistant gram negative isolates in a multi-disciplinary hospital. J Infect 2010; 61: 358-9.
30. Hoban DJ, Bouchillon SK, Johnson BM et al. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn Microbiol Infect Dis 2005; 52: 215-27.
31. Dean CR, Visalli MA, Projan SJ et al. Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother 2003; 47: 972-8.
32. Visalli MA, Murphy E, Projan SJ et al. AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis. Antimicrob Agents Chemother 2003; 47: 665-9.
33. Akiyama T, Presedo J, Khan AA. The tetA gene decreases tigecycline sensitivity of Salmonella enterica isolates. Int J Antimicrob Agents 2013; 42: 133-40.
34. Hentschke M, Christner M, Sobottka I et al. Combined ramR mutation and presence of a Tn1721-associated tet(A) variant in a clinical isolate of Salmonella enterica serovar Hadar resistant to tigecycline. Antimicrob Agents Chemother 2010; 54: 1319-22.
35. Tuckman M, Petersen PJ, Projan SJ. Mutations in the interdomain loop region of the tetA(A) tetracycline resistance gene increase efflux of minocycline and glycylcyclines. Microb Drug Resist 2000; 6: 277-82.
36. McAleese F, Petersen P, Ruzin A et al. A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline. Antimicrob Agents Chemother 2005; 49: 1865-71.
37. Moore IF, Hughes DW,Wright GD. Tigecycline is modified by the flavindependent monooxygenase TetX. Biochemistry 2005; 44: 11829-35.
38. Volkers G, Palm GJ, Weiss MS et al. Structural basis for a new tetracycline resistance mechanism relying on the TetX monooxygenase. FEBS Lett 2011; 585: 1061-6.
39. Villa L, Feudi C, Fortini D et al. Genomics of KPC-producing Klebsiella pneumoniae sequence type 512 clone highlights the role of RamR and ribosomal S10 protein mutations in conferring tigecycline resistance. Antimicrob Agents Chemother 2014; 58: 1707-12.
40. Cattoir V, Isnard C, Cosquer T et al. Genomic analysis of reduced susceptibility to tigecycline in Enterococcus faecium. Antimicrob Agents Chemother 2015; 59: 239-44.
41. Chen Q, Li X, Zhou H et al. Decreased susceptibility to tigecycline in Acinetobacter baumannii mediated by a mutation in trm encoding SAM-dependent methyltransferase. J Antimicrob Chemother 2014; 69: 72-6.
42. Linkevicius M, Sandegren L, Andersson DI. Mechanisms and fitness costs of tigecycline resistance in Escherichia coli. J Antimicrob Chemother 2013; 68: 2809-19.
43. Hoskins J, Alborn WE Jr, Arnold J et al. Genome of the bacterium Streptococcus pneumoniae strain R6. J Bacteriol 2001; 183: 5709-17.
44. Tygacilw Product Insert. http://www.pfizerpro.com/hcp/tygacil.
45. Fani F, Leprohon P, Zhanel GG et al. Genomic analyses of DNA transformation and penicillin resistance in Streptococcus pneumoniae clinical isolates. Antimicrob Agents Chemother 2014; 58: 1397-403.
46. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 2014; 30: 2114-20.
47. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009; 25: 1754-60.
48. Li H, Handsaker B, Wysoker A et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 2009; 25: 2078-9.
49. Lupien A, Billal DS, Fani F et al. Genomic characterization of ciprofloxacin resistance in a laboratory-derived mutant and a clinical isolate of Streptococcus pneumoniae. Antimicrob Agents Chemother 2013; 57: 4911-9.
50. Billal DS, Feng J, Leprohon P et al. Whole genome analysis of linezolid resistance in Streptococcus pneumoniae reveals resistance and compensatory mutations. BMC Genomics 2011; 12: 512.
51. Fani F, Brotherton MC, Leprohon P et al. Genomic analysis and reconstruction of cefotaxime resistance in Streptococcus pneumoniae. J Antimicrob Chemother 2013; 68: 1718-27.
52. Le SQ, Gascuel O. An improved general amino acid replacement matrix. Mol Biol Evol 2008; 25: 1307-20.
53. Tamura K, Stecher G, Peterson D et al. MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. Mol Biol Evol 2013; 30: 2725-9.
54. Lupien A, Gingras H, Bergeron MG et al. Multiple mutations and increased RNA expression in tetracycline-resistant Streptococcus pneumoniae as determined by genome-wide DNA and mRNA sequencing. J Antimicrob Chemother 2015; 70: 1946-59.
55. Kilian M, Poulsen K, Blomqvist T et al. Evolution of Streptococcus pneumoniae and its close commensal relatives. PLoS One 2008; 3: e2683.
56. Fani F, Leprohon P, Legare D et al. Whole genome sequencing of penicillin-resistant Streptococcus pneumoniae reveals mutations in penicillin-binding proteins and in a putative iron permease. Genome Biol 2011; 12: R115.
57. Feng J, Lupien A, Gingras H et al. Genome sequencing of linezolidresistant Streptococcus pneumoniae mutants reveals novel mechanisms of resistance. Genome Res 2009; 19: 1214-23.
58. Lesnyak DV, Osipiuk J, Skarina T et al. Methyltransferase that modifies guanine 966 of the 16 S rRNA: functional identification and tertiary structure. J Biol Chem 2007; 282: 5880-7.
59. Sergiev PV, Bogdanov AA, Dontsova OA. Ribosomal RNA guanine-(N2)-methyltransferases and their targets. Nucleic Acids Res 2007; 35: 2295-301.
60. Sun Y, Cai Y, Liu X et al. The emergence of clinical resistance to tigecycline. Int J Antimicrob Agents 2013; 41: 110-6.
61. Brodersen DE, Clemons WM Jr, Carter AP et al. The structural basis for the action of the antibiotics tetracycline, pactamycin, and hygromycin B on the 30S ribosomal subunit. Cell 2000; 103: 1143-54.
62. Hu M, Nandi S, Davies C et al. High-level chromosomally mediated tetracycline resistance in Neisseria gonorrhoeae results from a point mutation in the rpsJ gene encoding ribosomal protein S10 in combination with the mtrR and penB resistance determinants. Antimicrob Agents Chemother 2005; 49: 4327-34.
63. Luo X, Hsiao HH, Bubunenko M et al. Structural and functional analysis of the E. coli NusB-S10 transcription antitermination complex. Mol Cell 2008; 32: 791-802.
64. Squires CL, Zaporojets D. Proteins shared by the transcription and translation machines. Annu Rev Microbiol 2000; 54: 775-98.
65. Weisberg RA. Transcription by moonlight: structural basis of an extraribosomal activity of ribosomal protein S10. Mol Cell 2008; 32: 747-8.
66. Buck MA, Cooperman BS. Single protein omission reconstitution studies of tetracycline binding to the 30S subunit of Escherichia coli ribosomes. Biochemistry 1990; 29: 5374-9.
67. Olson MW, Ruzin A, Feyfant E et al. Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob Agents Chemother 2006; 50: 2156-66.
68. Trieber CA, Taylor DE. Mutations in the 16S rRNA genes of Helicobacter pylori mediate resistance to tetracycline. J Bacteriol 2002; 184: 2131-40.
69. Ross JI, Eady EA, Cove JH et al. 16S rRNA mutation associated with tetracycline resistance in a gram-positive bacterium. Antimicrob Agents Chemother 1998; 42: 1702-5.